Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The study was prematurely discontinued on 14 September 2011 due to no significant pharmacological effects (safety/PD/efficacy) through 25 mg/kg cohort, the T1/2 based on VEGF binding was shorter than expected and the current and/or higher doses were not considered feasible for further development. There were no safety concerns associated with the decision to terminate the program/study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed solid tumors unresponsive to current therapy or for which there is no standard therapy.
Stage 2 only: Histologically or cytologically documented EOC or PPC with \< or equal to 3 previous anti-cancer therapies, but at least 1 prior platinum containing regimen.
Adequate coagulation, liver, and renal function.
Candidate for Dynamic Contrast-Enhanced Magnetic Resonance Imaging \[DCE-MRI\] evaluation
Eastern Cooperative Oncology Group \[ECOG\] performance status of 0 or 1
You may not be if
History of clinically significant toxicity to Vascular Endothelial Growth Factor \[VEGF\] inhibition.
Evidence of bleeding problems.
Uncontrolled hypertension.
Patients with primary brain cancer and/or non-small cell lung cancer of squamous cell histology
Clareo Health | A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors
